Simplex Trading
INZY

Simplex Trading’s Inozyme Pharma INZY Stock Holding History

Simplex Trading’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-500
Closed -$1K – 9027
2024
Q4 		$1K Sell
500
-700
-58% -$2.66K ﹤0.01% 8221
2024
Q3 		$6K Sell
1,200
-400
-25% -$2.08K ﹤0.01% 7522
2024
Q2 		$7K Sell
1,600
-8,500
-84% -$41.2K ﹤0.01% 7675
2024
Q1 		$77K Sell
10,100
-2,600
-20% -$14.3K ﹤0.01% 5855
2023
Q4 		$54K Buy
12,700
+5,900
+87% +$21K ﹤0.01% 6012
2023
Q3 		$28K Buy
+6,800
New +$34.6K ﹤0.01% 6316
2023
Q2 		– Sell
-3,600
Closed -$20K – 9427
2023
Q1 		$20K Buy
+3,600
New +$9.51K ﹤0.01% 6911

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Simplex Trading's INZY Position: Q2 2025 in Review

Simplex Trading sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 16,349 shares — an estimated $40.5K sold.

Simplex Trading first reported a position in INZY in Q4 2022 and held it in 9 quarters. The position peaked at $23K in Q1 2023. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • Simplex Trading reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • Simplex Trading sold 16,349 Inozyme Pharma shares in Q2 2025, an estimated $40.5K.
  • Simplex Trading first reported a position in Inozyme Pharma in Q4 2022 and held it in 9 quarters.
  • Simplex Trading's Inozyme Pharma position peaked at $23K in Q1 2023.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on Simplex Trading's 13F filing for Q2 2025, filed 5 Aug 2025.